Catálogo de publicaciones - revistas

Compartir en
redes sociales


European Journal of Heart Failure

Resumen/Descripción – provisto por la editorial

No disponible.

Palabras clave – provistas por la editorial

No disponibles.

Disponibilidad
Institución detectada Período Navegá Descargá Solicitá
No detectada desde ene. 1999 / hasta dic. 2023 Wiley Online Library

Información

Tipo de recurso:

revistas

ISSN impreso

1388-9842

ISSN electrónico

1879-0844

País de edición

Estados Unidos

Cobertura temática

Tabla de contenidos

Heart Failure Diagnosis in the General Community ‐ Who, How and When? A clinical consensus statement of the Heart Failure Association (HFA) of the ESC

Kieran F. Docherty; Carolyn S.P. Lam; Amina Rakisheva; Andrew J.S. Coats; Trisha Greenhalgh; Marco Metra; Mark C. Petrie; Giuseppe M.C. Rosano

Palabras clave: Cardiology and Cardiovascular Medicine.

Pp. No disponible

Using combinational diuretics across the spectrum of renal function

Pieter Martens; Wilfried Mullens

Palabras clave: Cardiology and Cardiovascular Medicine.

Pp. No disponible

State‐of‐the‐art document on optimal contemporary management of cardiomyopathies

Petar M. Seferović; Marija Polovina; Giuseppe Rosano; Biykem Bozkurt; Marco Metra; Stephane Heymans; Wilfried Mullens; Johann Bauersachs; Karen Sliwa; Rudolf A. de Boer; Dimitrios Farmakis; Thomas Thum; Iacopo Olivotto; Claudio Rapezzi; Aleš Linhart; Domenico Corrado; Carsten Tschöpe; Ivan Milinković; Antoni Bayes Genis; Gerasimos Filippatos; Andre Keren; Milika Ašanin; Gordana Krljanac; Ružica Maksimović; Hadi Skouri; Tuvia Ben Gal; Brenda Moura; Maurizio Volterrani; Magdy Abdelhamid; Yuri Lopatin; Ovidiu Chioncel; Andrew J.S. Coats

<jats:title>Abstract</jats:title><jats:p>Cardiomyopathies represent significant contributors to cardiovascular morbidity and mortality. Over the past decades, a progress has occurred in characterization of the genetic background and major pathophysiological mechanisms, which has been incorporated into a more nuanced diagnostic approach and risk stratification. Furthermore, medications targeting core disease processes and/or their downstream adverse effects have been introduced for several cardiomyopathies. Combined with standard care and prevention of sudden cardiac death, these novel and emerging targeted therapies offer a possibility of improving the outcomes in several cardiomyopathies. Therefore, the aim of this document is to summarize practical approaches to the treatment of cardiomyopathies, which includes the evidence‐based novel therapeutic concepts and established principles of care, tailored to the individual patient aetiology and clinical presentation of the cardiomyopathy. The scope of the document encompasses contemporary treatment of dilated, hypertrophic, restrictive and arrhythmogenic cardiomyopathy. It was based on an expert consensus reached at the Heart Failure Association online Workshop, held on 18 March 2021.</jats:p>

Palabras clave: Cardiology and Cardiovascular Medicine.

Pp. No disponible